



October 30, 2025

**Fourth Report to Court of
KSV Restructuring Inc. in its capacity
as Proposal Trustee of lovate Health
Sciences International Inc.,
lovate Health Sciences U.S.A. Inc. and
Northern Innovations Holding Corp.**

and

**Report of KSV Restructuring Inc. as
Proposed CCAA Monitor of Xiwang
lovate Holdings Company Limited,
lovate Health Sciences International
Inc., lovate Health Sciences U.S.A. Inc.,
lovate Health Sciences Australia PTY
Ltd. and Northern Innovations Holding
Corp.**

Contents

Page

1.0	Introduction	1
1.1	Purposes of this Report.....	3
1.2	Restrictions	4
1.3	Currency	4
2.0	Background	4
3.0	Activities of the Proposal Trustee	5
4.0	Developments Since the Third Report	5
4.1	Orgain, Inc.	5
4.2	Kenco Logistic Services, LLC	6
5.0	Continuation of the NOI Proceedings under the CCAA.....	7
6.0	Proposed Continuation and Granting of Court Charges	8
7.0	Foreign Representative and Recognition	8
8.0	Stay of Proceedings	9
9.0	Qualifications to Act as Monitor	10
10.0	Cash Flow Forecast.....	10
11.0	Sale and Investment Solicitation Process	10
12.0	Conclusion and Recommendation	11

Appendices

Appendix

Tab

Cash Flow Forecast and Management's Report on Cash Flow.....	A
Proposed Monitor's Report on Cash Flow	B

Court File No. BK-25-03268936-0031

ONTARIO
SUPERIOR COURT OF JUSTICE
(COMMERCIAL LIST)

Court No.: 31-3268942
Estate No.: 31-3268942

IN THE MATTER OF THE NOTICE OF INTENTION TO MAKE A PROPOSAL OF
IOVATE HEALTH SCIENCES INTERNATIONAL INC.

Court No.: 31-3268942
Estate No.: 31-3268942

IN THE MATTER OF THE NOTICE OF INTENTION TO MAKE A PROPOSAL OF
IOVATE HEALTH SCIENCES U.S.A. INC.

Court No.: 31-3268971
Estate No.: 31-3268971

IN THE MATTER OF THE NOTICE OF INTENTION TO MAKE A PROPOSAL OF
NORTHERN INNOVATIONS HOLDING CORP.

FOURTH REPORT OF KSV RESTRUCTURING INC. AS
PROPOSAL TRUSTEE AND PRE-FILING REPORT OF KSV
RESTRUCTURING INC. AS PROPOSED MONITOR

OCTOBER 30, 2025

1.0 Introduction

1. On September 5, 2025, Iovate Health Sciences International Inc. ("**Iovate International**"), Iovate Health Sciences U.S.A. Inc. ("**Iovate USA**") and Northern Innovations Holding Corp. ("**Northern Innovations**") and collectively, the "**NOI Applicants**") each filed a Notice of Intention to Make a Proposal (collectively the "**NOIs**", each an "**NOI**") in accordance with the *Bankruptcy and Insolvency Act*, R.S.C. 1985, c. B-3, as amended (the "**BIA**"), and KSV Restructuring Inc. ("**KSV**") consented to act as proposal trustee (in such capacity, the "**Proposal Trustee**").
2. On September 9, 2025, the Ontario Superior Court of Justice (Commercial List) (the "**Canadian Court**") granted an order (the "**September 9 Order**"):
 - a) granting an administrative consolidation of the proposal proceedings (the "**NOI Proceedings**") under one title of proceedings;

- b) granting a charge over the assets, undertakings and properties of the NOI Applicants to secure payment of the fees and disbursements of certain administrative professionals (the “**Administrative Professionals Charge**”), up to an amount of CAD \$750,000;
 - c) authorizing Iovate International to act as foreign representative for the purpose of having the NOI Proceedings recognized in a jurisdiction outside of Canada; and
 - d) authorizing Iovate International, as foreign representative, to apply for relief pursuant to Chapter 15 of the U.S. Bankruptcy Code.
3. On September 10, 2025, the U.S. Bankruptcy Court for the Southern District of New York (the “**New York Court**”) entered an order (the “**Provisional Order**”) provisionally recognizing Iovate International as foreign representative of the NOI Applicants with full authority to administer their assets and affairs in the United States (the “**Chapter 15 Proceedings**”). The Provisional Order also provided that section 362 of the U.S. Bankruptcy Code applies with respect to the NOI Applicants and the property of each NOI Applicant that is within the territorial jurisdiction of the United States. The Provisional Order was extended pursuant to an order granted by the New York Court on September 19, 2025.
4. On October 3, 2025, the Canadian Court granted an order (the “**October 3 Order**”), among other things, extending the time for the NOI Applicants to file a proposal in the NOI Proceedings to and including November 4, 2025.
5. On October 17, 2025, the Canadian Court granted an order, among other things, approving a settlement agreement between Iovate USA and Kenco Logistic Services, LLC (“**Kenco**”) dated October 8, 2025 (the “**Settlement Agreement**”), and the associated mutual release. The Court declined to make any order regarding the stay under section 362 of the U.S. Bankruptcy Code and declined to schedule the related case conference requested by Orgain, Inc. (“**Orgain**”).
6. On October 28, 2025, the New York Court, among other things:
- a) recognized the NOI Proceedings as the foreign main proceeding pursuant to section 1517 of the U.S. Bankruptcy Code and granted the protection afforded by the automatic stay of proceedings to the NOI Applicants and to the NOI Applicants’ property that is within the United States; and
 - b) ordered Walmart to turn over all amounts owing to the NOI Applicants by Walmart as a result of the Writ and as due in the ordinary course of business.
7. KSV is filing this joint report (the “**Joint Report**”) in its capacities as: (i) the Proposal Trustee of the NOI Applicants; and (ii) Proposed Monitor (defined below) to Xiwang Iovate Holdings Company Limited (“**Xiwang Iovate**”), Iovate International, Iovate USA, Northern Innovations and Iovate Health Sciences Australia Pty Ltd. (“**Iovate Australia**”, and collectively, the “**Applicants**”)
8. Capitalized terms not defined herein have the meaning ascribed to them in the Affidavit of Wesley Parris sworn October 29, 2025 (the “**October 29 Affidavit**”) filed in support of the Applicants’ motion.

1.1 Purposes of this Report

1. The purposes of this Joint Report are to:
 - a) provide background information about the NOI Applicants, the NOI Proceedings and the proposed CCAA Proceedings (defined below);
 - b) provide KSV's recommendation in support of the Applicants' motion to:
 - i. declare that each of the Applicants is a "debtor company" to which the CCAA applies;
 - ii. direct that the NOI Proceedings be taken up and continued under the CCAA (the "**CCAA Proceedings**");
 - iii. appoint KSV as an officer of the Court in the proposed CCAA Proceedings to monitor the assets, business, and affairs of the Applicants (the "**Proposed Monitor**" and once appointed in such capacity, the "**Monitor**");
 - iv. grant a Stay of Proceedings until December 12, 2025;
 - v. extend the benefit of the Stay of Proceedings and other aspects of the Initial Order to the Non-Applicant Stay Parties¹;
 - vi. order that the September 9 Order, the October 3 Order and the Order of Justice W.D. Black granted October 17, 2025 and the authorizations, rights, protections and other relief granted thereunder shall continue in full force and effect in the CCAA Proceedings;
 - vii. expand the September 9 Order to appoint Iovate International as the foreign representative of the Iovate Group (the "**Foreign Representative**") in respect of these CCAA Proceedings and authorize the Foreign Representative to apply for relief pursuant to Chapter 15 of the U.S. Bankruptcy Code; and
 - viii. continue or grant (as applicable) the Charges (as defined below) over all of the Applicants' current and future assets, property and undertaking (collectively, the "**Property**");
 - c) provide KSV's qualifications to act as Monitor in the proposed CCAA Proceedings;
 - d) report on the Applicants' cash flow projection for the period ending December 12, 2025 (the "**Cash Flow Forecast**"); and
 - e) report on the Proposal Trustee's activities and the recommendations of KSV as Proposal Trustee and Proposed Monitor in connection with the foregoing.

¹ Non-Applicant Stay Parties include: Infinity Insurance Co. Ltd. ("**Infinity Insurance**"), Iovate Health Sciences Europe Limited ("**Iovate Europe**"), Muscletech LLC ("**Muscletech**"), XP Sports LLC ("**XP Sports**"), and Simplevita Nutrition LLC ("Simplevita") (collectively, the "**Non-Applicant Stay Parties**", and together with the Applicants, the "**Iovate Group**").

1.2 Restrictions

1. In preparing this Joint Report, KSV has relied upon the Applicants' audited and unaudited financial information, the books and records of the Applicants, and discussions with the Applicants' representatives, legal counsel and financial advisor.
2. KSV has not audited or otherwise attempted to verify the accuracy or completeness of the financial information relied on to prepare this Joint Report in a manner that complies with Canadian Auditing Standards ("**CAS**") pursuant to the Chartered Professional Accountants of Canada Handbook and, accordingly, KSV expresses no opinion or other form of assurance contemplated under the CAS in respect of such information. Any party wishing to place reliance on the financial information should perform its own diligence.
3. An examination of the Cash Flow Forecast as outlined in the Chartered Professional Accountants of Canada Handbook has not been performed. Future oriented financial information relied upon in this Joint Report is based on the Applicants' assumptions regarding future events; actual results achieved may vary from this information and these variations may be material. KSV expresses no opinion or other form of assurance on whether the Cash Flow Forecast will be achieved.

1.3 Currency

1. Unless otherwise noted, all currency references in this Joint Report are in U.S Dollars.

2.0 Background

1. The October 29 Affidavit in connection with this motion provides detailed background information with respect to the Applicants' business and operations. Accordingly, only a summary of that information is included in this Joint Report.
2. The Applicants are part of the lovate Group, a group of companies engaged in the development, production and sale of health and nutrition products in Canada, the United States and internationally. The lovate Group's key brands include MuscleTech™, Hydroxycut™, Six Star®, and Purely Inspired®, which are sold in over 90 countries worldwide.
3. Since the commencement of the NOI Proceedings, the NOI Applicants, with the assistance of the Proposal Trustee, have stabilized operations, maintained supply relationships, and continued normal business activities. In particular, the NOI Applicants, with the assistance of the Proposal Trustee, have worked to resolve two critical issues, as detailed further in Section 4.0 of this Joint Report:
 - a) first, the parties negotiated and arranged a consensual resolution of the dispute with Kenco, which was approved by the Court on October 17, 2025; and
 - b) second, the parties obtained an Order from the New York Court directing Walmart to promptly release all monies being held by Walmart in relation to the Writ (as defined below) and remit all payments owed to the NOI Applicants in the ordinary course of business.

4. The October 29 Affidavit, all Court Orders granted in the NOI Proceedings and the Reports filed by KSV in its capacity as Proposal Trustee are available on KSV's website at the following link: <https://www.ksvadvisory.com/experience/case/lovate>.

3.0 Activities of the Proposal Trustee

1. Since the delivery of the Third Report of the Proposal Trustee dated October 15, 2025 (the "**Third Report**"), the Proposal Trustee has engaged in the following activities, certain of which are detailed further in the sections below:
 - a) assisting the NOI Applicants in their communications to suppliers and other stakeholders;
 - b) assisting the Applicants in the preparation of the Cash Flow Forecast;
 - c) assisting the NOI Applicants in their negotiation with and performance of the Settlement Agreement with Kenco;
 - d) assisting the NOI Applicants to negotiate and obtain the release of the receivables being held by Walmart;
 - e) engaging with investment-banking firms to submit proposals in connection with a proposed SISP (defined below);
 - f) assisting the Applicants in the preparation and design of the proposed SISP;
 - g) attending calls and email correspondence with the Applicants, the Applicants' legal counsel and the Proposal Trustee's counsel, Osler, Hoskin & Harcourt LLP, regarding all matters in connection with the NOI Proceeding and the proposed CCAA Proceeding; and
 - h) with the assistance of its legal counsel, preparing this Joint Report.

4.0 Developments Since the Third Report

4.1 Orgain, Inc.

1. In the U.S. District Court for the Central District of California, a jury returned a verdict against lovate International and lovate USA on September 6, 2023, and the court entered judgment on April 17, 2024 in the amount of \$10,035,481 plus costs.
2. The parties initially appeared to have reached an agreement in principle regarding settlement terms; however, a dispute later arose as to whether a binding settlement had in fact been concluded.
3. On November 17, 2024, the court entered an Amended Judgment of \$12,500,000, for which lovate International and lovate USA are jointly and severally liable.
4. To enforce the Amended Judgment, Orgain pursued garnishments against receivables from major customers, including Walmart, Amazon, GNC, and Vitamin Shoppe. Walmart specifically accounts for a significant amount of the lovate Group's receipts.

5. Orgain obtained a writ of garnishment in Arkansas on June 27, 2025 (the “**Writ**”) and subsequently served Walmart with the Writ. Walmart then froze and withheld payments to Iovate USA beginning around August 4, 2025.
6. Iovate International and Iovate USA’s motion to quash the Writ was heard and denied by the Circuit Court of Benton County, Arkansas (the “**Arkansas Court**”) on August 25, 2025.
7. On August 27, 2025, the Lenders delivered letters demanding immediate repayment of the outstanding indebtedness under the Credit Agreement, stating that several Events of Default under the Credit Agreement had occurred, and delivered notices of intention to enforce security under Section 244 of the BIA.
8. After Iovate commenced the NOI Proceedings and the Chapter 15 Proceedings, a Notice of Bankruptcy was filed with the Arkansas Court. The Arkansas Court closed the garnishment case on September 25, 2025, pending resolution of the insolvency proceedings.
9. As of October 3, 2025, Walmart owed the Applicants approximately \$21.5 million. Walmart resumed some payments from October 8, 2025, releasing about \$3.4 million, however Walmart continues to retain approximately \$13.7 million in relation to the Amended Judgment, which continues to restrict the Iovate Group’s liquidity.
10. In the Chapter 15 Proceedings, as part of the Recognition Motion, Iovate sought an order explicitly directing Walmart to remit the withheld funds. Orgain responded by filing: (i) a motion in Canada on October 14, 2025, seeking to lift the BIA stay to allow it to continue garnishment proceedings commenced by it in the Arkansas Court, and (ii) a limited objection in the Chapter 15 case on October 15, 2025, asking the U.S. Court not to require full turnover of the Walmart funds. On October 20, 2025, the Canadian Court declined to schedule Orgain’s motion, noting that Judge Glenn and the New York Court were the appropriate tribunal to determine matters under section 362 of the U.S. Bankruptcy Code.
11. On October 28, 2025, Judge Glenn entered an order, among other things, directing the Foreign Representative to take immediate possession of the Walmart Receivable (being the receivable due and owing from Walmart to the NOI Applicants as of September 5, 2025), requiring Walmart to turn over all monies being held by Walmart as a result of the Writ and to continue to remit all monies owing to the NOI Applicants in the ordinary course of business.

4.2 Kenco Logistic Services, LLC

1. Iovate USA transitioned its distribution in the United States from an in-house facility in Buffalo to Kenco in September 2023 under a Warehousing & Logistics Services Agreement dated April 27, 2023.
2. By mid-2024, third-party logistics costs were significantly over budget, and in December 2024, Iovate USA decided to transition operations to RJW Logistics Group even though the Kenco contract remained in force.
3. During the summer of 2025, Iovate USA and Kenco negotiated an early termination framework that contemplated ongoing services at roughly \$900,000 per month, approximately \$1.8 million in arrears, and a transition fee of about \$3.7 million.

4. On September 23, 2025, Kenco filed an emergency motion in the Chapter 15 case seeking expedited stay relief or adequate protection based on a claimed general warehouseman's lien and asserted termination-related obligations exceeding \$8.5 million; expedited relief was denied. As of early October 2025, Kenco held approximately \$18 million of Iovate USA inventory, and its services were still needed through to the end of October.
5. On October 8, 2025, Iovate USA and Kenco executed the Settlement Agreement. The Settlement Agreement provides that: i) Iovate USA will pay to the Proposal Trustee, \$2.8 million to be held in escrow for Kenco until court approval; ii) payment to Kenco of all post-petition services and a prepayment for October services (to the extent there is any overpayment, the overpayment will be credited back to Iovate USA within thirty days of payment), iii) Kenco's continued cooperation and services until all goods left its facility, and iv) mutual releases which will provide a full and final resolution to the dispute.
6. On October 17, 2025, the Canadian Court approved the Settlement Agreement, after which the \$2.8 million was released to Kenco and the settlement terms were implemented.

5.0 Continuation of the NOI Proceedings under the CCAA

1. The Applicants are seeking an order to commence, or continue the NOI Proceeding (as applicable), under the CCAA.
2. The NOI Proceedings were initiated on an urgent basis to provide the NOI Applicants with time to address their liquidity issues. The Applicants are insolvent and require additional time to complete their restructuring efforts to maximize value for the Applicants' stakeholders.
3. The NOI Applicants' restructuring efforts since commencement of the NOI Proceedings have focused on improving and maintaining their liquidity position and pursuing a going-concern solution for the business in Canada.
4. As described in further detail in the October 29 Affidavit, the Applicants now seek to commence, or continue the NOI Proceedings (as applicable), under the CCAA to, among other things, provide the Applicants with the time, flexibility and stability to maintain the Iovate Group as a going concern business and undertake an orderly restructuring process, which will likely be in the form of a SISF described in further detail below. The Applicants also seek to continue with full force and effect, the authorizations, rights, protections and other relief granted by the September 9 Order, the October 3 Order and the October 17 Order, in the CCAA Proceedings.
5. In the Proposed Monitor's view, continuation of the NOI Proceedings under the CCAA and commencement of the CCAA Proceeding in respect of Xiwang Iovate and Iovate Australia, is appropriate and consistent with the CCAA's objectives to allow debtors to continue to carry on business and avoid the social and economic costs of liquidating its assets. Further, the continuation of the Orders previously granted in the NOI Proceedings is appropriate as the NOI Applicants will continue to require the benefit of these Orders in the context of the CCAA Proceedings.

6.0 Proposed Continuation and Granting of Court Charges

1. The September 9 Order approved a CAD \$750,000 charge securing the fees and disbursements of the Proposal Trustee, its counsel, U.S. counsel and Canadian counsel for the NOI Applicants, and KPMG LLP in its capacity as the Financial Advisor to the NOI Applicants.
2. The Initial Order contemplates an order:
 - a) continuing the Administrative Professionals Charge up to a maximum amount of CAD \$750,000 and including FTI Consulting, in its capacity as financial advisor to the Lenders, and Blake, Cassels & Graydon LLP, as counsel to the Lenders, among the Administrative Professionals that are beneficiaries under the Administrative Professionals Charge; and
 - b) granting a priority charge in favour of the Directors and Officers in the amount of CAD \$1,310,000 (the “**Directors’ Charge**”, together with the Administrative Professionals Charge, the “**Charges**”).
3. The Administrative Professionals Charge shall be a charge over the Property of the Applicants and is proposed to rank ahead of and have priority over all existing claims and encumbrances and the Directors’ Charge. The proposed Initial Order contemplates that the Directors’ Charge will rank subordinate to the Administrative Professionals Charge, but in priority to all other claims and encumbrances.
4. The Proposed Monitor has assisted the Applicants in the calculation of the quantum of the Administrative Professionals Charge and the Directors’ Charge, taking into account a series of factors. Having regard to the nature, size and complexity of the proposed CCAA Proceeding, the Proposed Monitor is of the view that the Charges are reasonable and appropriate in the circumstances. The Proposed Monitor understands that the continuation and granting, as applicable, and quantum of the Charges is supported by the Lenders.
5. The Proposed Monitor believes that the Administrative Professionals Charge and the Director’s Charge continue to be appropriate and reasonable and the continuation and granting, as applicable, in the CCAA Proceedings ought to be approved.

7.0 Foreign Representative and Recognition

1. The Applicants seek to expand the September 9 Order to appoint Iovate International as the Foreign Representative for the Applicants within the CCAA Proceedings and to authorize Iovate International to apply for relief under Chapter 15 of the U.S. Bankruptcy Code.
2. Authorizing Iovate International to act as Foreign Representative and to seek recognition of the CCAA Proceedings, if granted, in the United States is consistent with the established principles of comity, cooperation between courts in cross-border insolvencies and will likely facilitate the restructuring of the Iovate Group on a cross-border basis.
3. The Proposed Monitor supports the request for Iovate International to act as the Foreign Representative for the Applicants within the CCAA Proceedings.

8.0 Stay of Proceedings

1. Pursuant to the October 3 Order, the current stay of proceedings is set to expire on November 4, 2025.
2. As part of the relief sought in the Initial Order, the Applicants request an extension of the Stay of Proceedings in the CCAA Proceedings to December 12, 2025 (the “**Stay Period**”). Given the integration of the Iovate Group’s business and operations, the Applicants also seek to extend the Stay to the Non-Applicant Stay Parties and their respective directors, officers, advisors (including counsel), and other representatives. This relief is intended to prevent uncoordinated enforcement actions in multiple jurisdictions and preserve enterprise value.
3. In the circumstances, the Proposed Monitor supports the granting of the relief requested and is of the view that it is reasonable and consistent with other cases where an NOI proceeding has been converted to a CCAA proceeding, as:
 - a) the key stakeholders have had notice of these NOI Proceedings since early September;
 - b) the proposed relief removing the need to return for a 10-day comeback has been granted by this Court in similar circumstances where:
 - i. the breadth of the proposed Stay of Proceedings is consistent with the scope of the stay of proceedings granted in the NOI Proceeding;
 - ii. the key stakeholders have had notice of the NOI Proceedings since early September; and
 - iii. in any event, the Applicants intend to return to Court within 13 days, on November 13, 2025, to seek approval of the SISF;
 - c) due to the integration of the business and operations of the Iovate Group, the Stay of Proceedings should be extended to the Iovate Group;
 - d) since the commencement of the NOI Proceedings, the NOI Applicants have continued to act in good faith and with due diligence;
 - e) the proposed Stay of Proceedings will allow the Applicants to continue to develop and finalize the terms of the SISF and engage an investment-banking firm to act as the investment bank in connection with the SISF;
 - f) the Applicants are expected to have sufficient liquidity to fund their operations, as reflected in the Cash Flow Forecast, through to the end of the proposed Stay Period; and
 - g) the Proposed Monitor does not believe any creditor will be prejudiced if the extension of the Stay of Proceedings is granted.
4. For the reasons set out immediately above, and in light of the underlying factors that support the Proposed Monitor’s recommendation to permit the NOI Proceeding to be continued under the CCAA, the Proposed Monitor is supportive of the extension of the Stay of Proceedings.

9.0 Qualifications to Act as Monitor

1. KSV is a licensed trustee within the meaning of section 2 of the BIA. In addition, KSV is not subject to any of the restrictions on who may be appointed as monitor set out in section 11.7(2) of the CCAA.
2. KSV has consented to act as Monitor in the proposed CCAA Proceeding should the Court grant the Initial Order. A copy of KSV's consent to act as Monitor is attached to the October 29 Affidavit as Exhibit "HH".
3. As KSV is presently the Proposal Trustee, it is familiar with the Applicants' business and operations and accordingly, it is logical and efficient for KSV to be appointed as Monitor.

10.0 Cash Flow Forecast

1. The Applicants have prepared the Cash Flow Forecast for the period from October 27, 2025 to December 12, 2025 (the "**Forecast Period**"), to align with the request for an extension of the Stay Period. The Cash Flow Forecast and the Applicants' statutory report thereon pursuant to Section 10(2)(b) of the CCAA are attached hereto Appendix "A".
2. The Proposed Monitor notes that the Applicants are expected to have sufficient liquidity to meet all of their day-to-day obligations during the Forecast Period.
3. The Cash Flow Forecast contemplates the payment of ongoing interest to the Lenders throughout the Forecast Period, reflecting the Applicants' continued commitment to maintain lender support and confidence.
4. Based on the Proposed Monitor's review of the Cash Flow Forecast, the cash flow assumptions appear reasonable. The Proposed Monitor's report on the Cash Flow Forecast is attached as Appendix "B".

11.0 Sale and Investment Solicitation Process

1. The Proposed Monitor, in consultation with the Applicants and the Lenders, is in the process of developing a sale and investment solicitation process ("**SISP**"), the terms of which are still in the process of being finalized, to pursue a going concern transaction for the benefit of the Iovate Groups' stakeholders.
2. The proposed SISP will provide for the Applicants and the Monitor to solicit interest in, and opportunities for: (a) one or more sale(s) or partial sale(s) of all, substantially all, or certain portions of the Iovate Group's business and/or property; and/or (b) an investment in, restructuring, recapitalization, refinancing or other form of reorganization of all or some of the Applicants or all or part of the Iovate Group's business.
3. The Proposed Monitor has initiated the process to obtain proposals from investment-banking firms to act as the investment bank in connection with the SISP. The proposals are due during the last week of October 2025. Once proposals are submitted, the Applicants, in consultation with the Lenders and the Monitor, will select the preferred investment-banking firm.

4. In this regard, the Applicants have scheduled a hearing for November 13, 2025 and will appear before the Canadian Court at that time to seek approval of the SISP.

12.0 Conclusion and Recommendation

1. KSV, both in its capacity as Proposal Trustee and the Proposed Monitor, is of the view that the relief sought in the proposed Initial Order is fair, reasonable, and necessary to stabilize operations, protect enterprise value, and maximize recoveries for the Applicants' stakeholders.
2. Based on the foregoing, KSV, both in its capacity as Proposal Trustee and the Proposed Monitor, respectfully recommends that this Honourable Court grant the Initial Order as requested by the Applicants.

* * *

All of which is respectfully submitted,

KSV Restructuring Inc.

**KSV RESTRUCTURING INC.,
IN ITS CAPACITY AS PROPOSAL TRUSTEE OF
IOVATE HEALTH SCIENCES INTERNATIONAL INC.,
IOVATE HEALTH SCIENCES U.S.A. INC. AND
NORTHERN INNOVATIONS HOLDING CORP.**

AND

**KSV RESTRUCTURING INC.,
IN ITS CAPACITY AS PROPOSED MONITOR OF
XIWANG IOVATE HOLDINGS COMPANY LIMITED
IOVATE HEALTH SCIENCES INTERNATIONAL INC.,
IOVATE HEALTH SCIENCES U.S.A. INC., IOVATE
HEALTH SCIENCES AUSTRALIA PTY LTD. AND
NORTHERN INNOVATIONS HOLDING CORP.
AND NOT IN ITS PERSONAL CAPACITY**

Appendix “A”

Xiwang Iovate Holdings Company Limited, Iovate Health Sciences International Inc., Iovate Health Sciences U.S.A. Inc., Iovate Health Sciences Australia Pty Ltd. and Northern Innovations Holding Corp. (collectively, the "Company")

Projected Weekly Cash Flow

For the 7-Week Period Ending December 12, 2025

(Unaudited; \$USD)

	Note	Week Ending						Total
		31-Oct	7-Nov	14-Nov	21-Nov	28-Nov	5-Dec	
	1							
<i>Receipts</i>								
Collections	2	3,919,963	16,262,599	5,887,668	3,872,471	3,172,177	5,307,291	41,995,374
<i>Total Receipts</i>		3,919,963	16,262,599	5,887,668	3,872,471	3,172,177	5,307,291	41,995,374
<i>Disbursements</i>								
Inventory Purchases	3	(3,000,000)	(3,000,000)	(3,000,000)	(3,000,000)	(3,000,000)	(3,000,000)	(21,000,000)
Operating Expenses	4	(2,631,525)	(993,967)	(605,580)	(756,524)	(1,460,298)	(1,255,266)	(8,301,423)
Payroll and Benefits	5	(325,293)	(325,293)	(325,293)	(326,413)	(286,413)	(286,413)	(2,161,531)
Occupancy costs	6	(100,000)	-	-	-	(100,000)	-	(200,000)
Other Expenses	7	(275,175)	(105,000)	289,500	-	-	-	(507,675)
<i>Total disbursements</i>		(6,331,993)	(4,424,261)	(3,641,374)	(4,082,937)	(4,846,711)	(4,541,679)	(32,170,628)
<i>Net Cash Flow before the Undemoted</i>		(2,412,030)	11,838,339	2,246,295	(210,466)	(1,674,534)	765,612	9,824,746
Professional Fees	8	(923,277)	(40,000)	(75,000)	(95,000)	(25,000)	(465,000)	(1,648,277)
Interest	9	-	(1,176,512)	-	-	(1,138,560)	-	(2,315,072)
<i>Net Cash Flow</i>		(3,335,307)	10,621,827	2,171,295	(305,466)	(2,838,094)	300,612	5,861,396
Opening Cash balance / (Deficit)		12,316,208	8,980,901	19,602,728	21,774,023	21,468,557	18,630,463	12,316,208
Net Cash Flow		(3,335,307)	10,621,827	2,171,295	(305,466)	(2,838,094)	300,612	5,861,396
Closing cash balance / (Deficit)		8,980,901	19,602,728	21,774,023	21,468,557	18,630,463	18,931,075	18,177,605

Xiwang Iovate Holdings Company Limited, Iovate Health Sciences International Inc., Iovate Health Sciences U.S.A. Inc., Iovate Health Sciences Australia Pty Ltd. and Northern Innovations Holding Corp. (collectively, the "Company")

Notes to Projected Weekly Cash Flow

For the 7-Week Period Ending December 12, 2025

(Unaudited; \$USD)

Purpose and General Assumptions

1. The purpose of the projection is to present a consolidated seven-week forecast of the Company for the period October 27, 2025 to December 12, 2025 (the "Period") in connection with the Company's proposed proceedings under the Companies' Creditors Arrangement Act ("CCAA").

The cash flow projection has been prepared based on hypothetical and most probable assumptions.

Hypothetical Assumptions

2. Reflects the estimated collections from the Company's sales in the normal course. The collections in the week ending November 7, 2025 assume that approximately \$12.3 million of net receivables (gross \$13.7 million) withheld by Walmart in connection with the litigation commenced by Orgain, Inc. will be released.

Probable Assumptions

3. Represents the estimated payments for inventory purchases.
4. Reflects estimated payments for operating expenses, including warehousing, freight, marketing and selling, general and administrative expenses.
5. Represents the gross payroll obligations for the Company's employees.
6. Reflects the Company's occupancy costs for headquarters in Oakville, Ontario.
7. Reflects payments for other expenses, including insurance, capital expenditures and post-filing sales taxes. The amount in the week ending November 14, 2025 reflects an estimated insurance refund.
8. Reflects estimated professional fees of the proposed Monitor, its counsel, the Company's Canadian and US counsel, the Company's financial advisor and the Company's secured lender's counsel and financial advisor.
9. Reflects interest payable on the Company's senior secured debt. Payment of this interest is contingent upon the collection of Walmart receivables (See Note 2).

COURT FILE NO.: BK-25-03268936-0031

**ONTARIO
SUPERIOR COURT OF JUSTICE
(COMMERCIAL LIST)**

**IN THE MATTER OF THE *COMPANIES' CREDITORS ARRANGEMENT ACT*,
R.S.C. 1985, c. C-36, AS AMENDED**

**AND IN THE MATTER OF A PLAN OF COMPROMISE OR
ARRANGEMENT OF XIWANG IOVATE HOLDINGS COMPANY
LIMITED, IOVATE HEALTH SCIENCES INTERNATIONAL INC.,
IOVATE HEALTH SCIENCES U.S.A. INC., IOVATE HEALTH
SCIENCES AUSTRALIA PTY LTD, and NORTHERN
INNOVATIONS HOLDING CORP.**

MANAGEMENT'S REPORT ON CASH FLOW STATEMENT
(paragraph 10(2)(b) of the CCAA)

The management of Xiwang Iovate Holdings Company Limited, Iovate Health Sciences International Inc., Iovate Health Sciences U.S.A. Inc., Iovate Health Sciences Australia Pty Ltd, And Northern Innovations Holding Corp. (collectively, the "Applicants") has developed the assumptions and prepared the attached consolidated statement of projected cash flow as of the 30th day of October, 2025, for the period October 27, 2025 to December 12, 2025 (the "Cash Flow Forecast"). All such assumptions are disclosed in the notes to the Cash Flow Forecast.

The hypothetical assumptions are suitably supported and consistent with the purpose of the Cash Flow Forecast as described in Note 1 to the Cash Flow Forecast, and the probable assumptions are suitably supported and consistent with the plans of the Applicants and provide a reasonable basis for the Cash Flow Forecast.


Since the Cash Flow Forecast is based on assumptions regarding future events, actual results will vary from the information presented and the variations may be material.

The Cash Flow Forecast has been prepared solely for the purpose outlined in Note 1 using a set of hypothetical and probable assumptions set out therein. Consequently, readers are cautioned that the Cash Flow Forecast may not be appropriate for other purposes.

Dated at Toronto, ON this 30th day of October, 2025.

**XIWANG IOVATE HOLDINGS COMPANY LIMITED, IOVATE HEALTH SCIENCES
INTERNATIONAL INC., IOVATE HEALTH SCIENCES U.S.A. INC., IOVATE HEALTH
SCIENCES AUSTRALIA PTY LTD, AND NORTHERN INNOVATIONS HOLDING CORP.**

Signed by:

A handwritten signature in blue ink that reads "Wes Parris".

E4D24112FEB2427...

Per: Wes Parris

Appendix “B”

COURT FILE NO.: BK-25-03268936-0031

**ONTARIO
SUPERIOR COURT OF JUSTICE
(COMMERCIAL LIST)**

**IN THE MATTER OF THE *COMPANIES' CREDITORS ARRANGEMENT ACT*,
R.S.C. 1985, c. C-36, AS AMENDED**

**AND IN THE MATTER OF A PLAN OF COMPROMISE OR
ARRANGEMENT OF XIWANG IOVATE HOLDINGS COMPANY
LIMITED, IOVATE HEALTH SCIENCES INTERNATIONAL INC.,
IOVATE HEALTH SCIENCES U.S.A. INC., IOVATE HEALTH
SCIENCES AUSTRALIA PTY LTD, and NORTHERN
INNOVATIONS HOLDING CORP.**

**PROPOSED MONITOR'S REPORT ON CASH FLOW
STATEMENT (paragraph 23(1)(b) of the CCAA)**

The attached consolidated statement of projected cash-flow of Xiwang Iovate Holdings Company Limited, Iovate Health Sciences International Inc., Iovate Health Sciences U.S.A. Inc., Iovate Health Sciences Australia Pty Ltd., and Northern Innovations Holding Corp. (collectively, the "Applicants"), Infinity Insurance Co. Ltd., Iovate Health Sciences Europe Limited, Muscletech LLC, XP Sports LLC, and Simplevita Nutrition LLC (collectively, the "Non-Applicant Stay Parties", and together with the Applicants, the "Iovate Group") as of the 30th day of October, 2025, consisting of a weekly projected cash flow statement for the period October 27, 2025 to December 12, 2025 (the "Cash Flow Forecast") has been prepared by the management of the Applicants for the purpose described in Note 1, using probable and hypothetical assumptions set out in the notes to the Cash Flow.

Our review consisted of inquiries, analytical procedures and discussions related to information supplied by the management of the Applicants. We have reviewed the support provided by management for the probable and hypothetical assumptions and the preparation and presentation of the Cash Flow Forecast.

Based on our review, nothing has come to our attention that causes us to believe that, in all material respects:

- a) the hypothetical assumptions are not consistent with the purpose of the Cash Flow Forecast;
- b) as at the date of this report, the probable assumptions developed by management are not suitably supported and consistent with the plans of the Applicants or do not provide a reasonable basis for the Cash Flow Forecast, given the hypothetical assumptions;
or
- c) the Cash Flow Forecast does not reflect the probable and hypothetical assumptions.

Since the Cash Flow Forecast is based on assumptions regarding future events, actual results will vary from the information presented, and the variations may be material. Accordingly, we express no assurance as to whether the Cash Flow Forecast will be achieved. We express no opinion or other form of assurance with respect to the accuracy of any financial information presented in this report, or relied upon in preparing this report.

The Cash Flow Forecast has been prepared solely for the purpose described in Note 1 and readers are cautioned that it may not be appropriate for other purposes.

Dated at Toronto, ON this 30th day of October, 2025.

KSV Restructuring Inc.

KSV RESTRUCTURING INC.,
solely in its capacity as proposed monitor of
Xiwang Iovate Holdings Company Limited,
Iovate Health Sciences International Inc.,
Iovate Health Sciences U.S.A. Inc.,
Iovate Health Sciences Australia Pty Ltd.
and Northern Innovations Holding Corp.

IN THE MATTER OF THE NOTICE OF INTENTION TO MAKE A PROPOSAL OF IOVATE HEALTH SCIENCES INTERNATIONAL INC.

COURT NO.: 31-3268936

ESTATE NO.: 31-3268936

IN THE MATTER OF THE NOTICE OF INTENTION TO MAKE A PROPOSAL OF IOVATE HEALTH SCIENCES U.S.A. INC.

COURT NO.: 31-3268942

ESTATE NO.: 31-3268942

IN THE MATTER OF THE NOTICE OF INTENTION TO MAKE A PROPOSAL OF NORTHERN INNOVATIONS HOLDING CORP.

COURT NO.: 31-3268971

ESTATE NO.: 31-3268971

Court File No. BK-25-03268936-0031

ONTARIO
SUPERIOR COURT OF JUSTICE
(COMMERCIAL LIST)

Proceeding commenced at: TORONTO

FOURTH REPORT OF THE PROPOSAL TRUSTEE
AND REPORT OF THE PROPOSED MONITOR
(OCTOBER 30, 2025)

OSLER, HOSKIN & HARCOURT LLP
100 King Street West, 1 First Canadian Place
Suite 6200, P.O. Box 50
Toronto ON M5X 1B8

Marc Wasserman (LSO# 44066M)

Tel: 416.862.4908

Email: mwasserman@osler.com

Michael DeLellis (LSO# 48038U)

Tel: 416.862.4923

Email: mdelellis@osler.com

Lawyers for KSV Restructuring Inc. in its capacity as Proposal Trustee and
Proposed Monitor